-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the academic journal Nano Letters published online the latest research results of Wang Yiguang's research team from the State Key Laboratory of Natural and Biomimetic Medicine, School of Pharmacy, Peking University, "A pH-/enzyme-responsive nanoparticle selectively targets endosomal Toll-like receptors to potentiate robust cancer vaccination.
In the treatment of malignant tumors, immunotherapy represented by immune checkpoint inhibitors, tumor vaccines, etc.
Wang Yiguang's research team designed a smart tumor nanovaccine ( TLR activating nanovaccine, TNV ) based on Toll -like receptor agonism based on the existing pH -sensitive ( Ultra-pH-sensitive, UPS ) nanotechnology platform of the research group.
In the nanovaccine TNV , the TLR7/8 agonist IMDQ was covalently bound to the hydrophobic block of the UPS polymer through an enzyme-sensitive bond GFLG , and formed nanomicelles through cooperative self-assembly .
Researcher Wang Yiguang of Peking University School of Pharmacy is the corresponding author of this research paper
From left: Qin Mengmeng, Wang Yiguang, Xia Heming
Original link: https://pubs.
About the Author:
Wang Yiguang, Ph.
(School of Pharmacy, Peking University)